Astrazeneca PLC

The number of biopharmaceutical injectable products continues to increase. Predictions are that 40 per cent of new molecular entities will require batch freeze-drying for stability. The freeze-drying process (lyophilization) removes water from sensitive or high-value products such as vaccines, biologics, antibiotics, to extend shelf-life without the need ...

In order to meet National and International medicines demand, both small and large pharmaceutical companies need to use multiple suppliers. It takes significant effort to coordinate these separate companies and create an integrated plan that safely ensures patients get the medicines they need. Any changes to the plan take time and effort to manage and thi...

The vision for this project is to create porosity between King's College London and AstraZeneca to facilitate the development of novel medicines that require advanced drug delivery systems. A senior academic from the Institute of Pharmaceutical Science, Professor Ben Forbes, will embed in projects within AstraZeneca to assess drug delivery strategies and ...

Drug discovery and biomedical research in academia relies heavily on the production of proteins for example in bioassays, high-throughput screening for novel active compounds and the determination of protein crystal structures. _However, producing and delivering a specific protein to partners in sufficient quality and quantity is often the first and rate-...

The varying success rates of cancer treatments demonstrate that one size does not fit all when it comes to therapeutic interventions. This is confirmed by the discovery of multiple genes that are responsible for the same disease, which determine how severely an individual may be impacted. If disease profiles are specific to an individual or a group of pat...

"Advance Therapies are a new generation of treatments which use patients' cells as 'drug' to treat a variety of diseases. Although encouraging results have been reported, this technology is complex, expensive and currently only available to small numbers of patients. We have formed the Innovate Manchester Advanced Therapy Centre Hub (iMATCH); this is a gr...

Chemical processes catalysed with Palladium (Pd) compounds, and based on Nobel-prize winning methods, have become essential for the production of life-enhancing pharmaceuticals & chemicals. These processes underpin global manufacturing worth more than £10billion each year for pharmaceuticals alone. However, the components of the Pd-catalyst must be recove...

Chiral amines are important building blocks used in 40% pharmaceutical products, 20% of crop protection compounds and are high value chemical intermediates. Current synthetic methods use wasteful resolution processes. This project will improve manufacturing efficiency by developing catalytic (transfer) hydrogenation methods to make specific types of chira...

New reactor technologies are set to allow products that have traditionally been made in batches to be produced in a continuous manner. These reactors have the potential to transform manufacturing sectors by reducing energy, waste and the cost of manufacture and distribution. The technology will allow companies to use a single reactor for a number of produ...

Background The use of high quality human biological samples with associated data and their effective life cycle management (biobanking) are increasingly critical to our understanding of the underlying mechanisms of disease and the development of diagnostics. However, despite much progress, the inadequate supply of quality samples and the excessive complex...

Molecular diagnostic tests have improved quality and reduced costs of cancer care, and are becoming more widely adopted in the NHS. The proposed programme will use novel next generation sequencing (NGS) and informatics to develop consistent, accurate tests for tumour profiling in order to identify therapeutic options, including enrolment into clinical tri...

Crystallisation is the most important means of purifying high value chemical products and then delivering them into forms that can be efficiently formulated. Crystal Growth Modifiers (CGM), are molecular analogues of the active ingredient co-generated in synthesis or additives incorporated into the formulation that strongly influence the crystal formation...